CMTM6 can modulate the stability of PD-L1 by reducing its ubiquitination [24, 29], and HER2 is degraded by proteolytic ubiquitination [15, 34]; therefore, CMTM6 may enhance the stability of HER2 protein in BC cells. The gene discussed is ERBB2; the disease is breast cancer.